Akso Health Group
NASDAQ:AHGFinancial - Credit Services
+$0.03 today
- Market cap
- $1.16B
- Beta
- -1.02
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$0.40
Volume 0.00M
Average 0.12M
AHG Pre-Tax Margin
Income before tax as a percentage of revenue.
Akso Health GroupNASDAQ: AHG
Pre-Tax Margin · Q4 FY2025 · quarter ended Mar 2025
Pre-tax margin narrows to -2113.3%
Pre-tax margin was -2113.3% in Q4 FY2025, down 1715.2 pp from a year earlier. On a trailing-twelve-month basis it was -1125.1%, down 748.6 pp year over year. Over 3 fiscal years it narrowed by 1058.3 pp.
Context
- Pre-tax margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1125.1%
- Year-over-year change
- -748.6pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | -1125.1% | -748.6pp |
| FY2024 | 2024-03-31 | -376.6% | -277.4pp |
| FY2023 | 2023-03-31 | -99.1% | -32.3pp |
| FY2022 | 2022-03-31 | -66.8% | +150.3pp |
| FY2021 | 2021-03-31 | -217.1% | — |
Pre-Tax Margin vs competitors
How AHG compares with its peers on the latest reported figures
- AHG's LTM Mar 2025 pre-tax margin of -1125.1% is the lowest of the 4 companies compared; the peer median is -0.9%.
- Its year-over-year change of -748.6 pp is the lowest of 4, against a peer median of +1.9 pp.
- Over three fiscal years its change of -1058.3 pp compares with a peer median of +7.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 15.6% | -1.1 pp | -0.2 pp | |
ZKHZKH Group Limited | LTM Mar 2026 | -0.9% | +1.9 pp | +7.3 pp |
| LTM Mar 2026 | -30.2% | +17.8 pp | +69.6 pp | |
| LTM Mar 2025 | -1125.1% | -748.6 pp | -1058.3 pp | |
| Peer median (excluding AHG) | -0.9% | +1.9 pp | +7.3 pp | |
Competitors are the stored peer set for AHG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 1.75M | 6M | 13.18M | 2.41M | 14.78M |
| Cost of Revenue | 544.57K | 5.39M | 11.91M | 2.29M | 15.06M |
| Gross Profit | 1.21M | 605.13K | 1.27M | 122.13K | (281.53K) |
| Gross Margin | 69.0% | 10.1% | 9.6% | 5.1% | -1.9% |
| Research & Development | 441.41K | 421.19K | 0 | 0 | 0 |
| Selling, General & Admin | 2.09M | 3.06M | 15.54M | 8.76M | 3.64M |
| Operating Expenses | 28.36M | 3.87M | 15.54M | 8.76M | 166.02M |
| Depreciation & Amortization | 15.16K | 18.39K | 18.39K | 8.64M | 2.15M |
| EBITDA | (28.9M) | (3.19M) | (14.27M) | (8.64M) | (1.77M) |
| EBITDA Margin | -1646.8% | -53.1% | -108.2% | -357.8% | -12.0% |
| Operating Income | (27.15M) | (3.26M) | (14.27M) | (8.64M) | (166.3M) |
| Operating Margin | -1547.1% | -54.3% | -108.2% | -357.8% | -1125.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.15M | 804.14K | 0 | 0 | 0 |
| Other Income / Expenses | 23.34M | (747.82K) | 1.2M | (453.75K) | 34.07K |
| Income Before Tax | (3.81M) | (4.01M) | (13.07M) | (9.09M) | (166.27M) |
| Pre-Tax Margin | -217.1% | -66.8% | -99.1% | -376.6% | -1125.1% |
| Income Tax Expense | 482.98K | 92.82K | 17.55K | 24.99K | (30.8M) |
| Net Income | (34.83M) | (16.85M) | (1.36M) | (9.46M) | (134.98M) |
| Net Margin | -1984.5% | -280.8% | -10.3% | -391.8% | -913.4% |
| EPS (Basic) | (0.26) | (2.55) | (0.06) | (0.45) | (0.48) |
| EPS (Diluted) | (0.27) | (2.55) | (0.06) | (0.39) | (0.48) |
| Weighted Avg Shares | 5.43M | 6.62M | 7.62M | 20.81M | 285.1M |
| Weighted Avg Shares (Diluted) | 5.43M | 6.62M | 7.62M | 23.83M | 285.1M |
Akso Health Group
NASDAQ:AHG
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.